Deletions of chromosomal arms 1p and 19q are frequent in oligodendroglial tumours and linked to radio-and chemotherapy response as well as longer survival. The molecular mechanisms underlying this clinically important association are as yet unknown. Here, we studied the peroxiredoxin 1 (PRDX1) gene at 1p34.1 for promoter methylation and expression in primary gliomas and investigated its role in radio-and chemosensitivity of glioma cells in vitro. In total, we screened primary glioma tissues from 93 patients for methylation of the 5 0 -CpG island of PRDX1 by sodium bisulfite sequencing. PRDX1 mRNA and protein expression levels were determined in subsets of the tumours by quantitative PCR and western blot analysis, respectively. PRDX1 hypermethylation and reduced expression were frequently detected in oligodendroglial tumours and secondary glioblastomas, but not in primary glioblastomas. In oligodendroglial tumours, both PRDX1 hypermethylation and reduced mRNA expression were significantly associated with 1p/19q-deletion. Stable knockdown of PRDX1 by lentiviral transduction of shorthairpin (sh)RNA constructs significantly increased apoptosis and reduced cell viability of Hs683 glioma cells exposed to ionizing irradiation or temozolomide in vitro. Taken together, our findings indicate that epigenetic silencing of PRDX1 is frequent in 1p/19q-deleted oligodendroglial tumours and likely contributes to radioand chemosensitivity of these tumours.
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Introduction
Oligodendroglial tumours are primary central nervous system tumours that account for B10-15% of all gliomas and comprise four histologically defined entities, namely well-differentiated oligodendrogliomas of World health organization (WHO) grade II, anaplastic oligodendrogliomas (WHO grade III), mixed oligoastrocytomas (WHO grade II) and anaplastic oligoastrocytomas (WHO grade III) (Louis et al., 2007) . Up to 80% of oligodendrogliomas and B50% of oligoastrocytomas show combined deletions of the chromosomal arms 1p and 19q (Reifenberger and Louis, 2003) mediated by an unbalanced t(1;19)(q10;p10) translocation (Griffin et al., 2006; Jenkins et al., 2006) . Deletion of 1p/19q was reported as an independent marker for favourable outcome in patients with anaplastic gliomas treated with chemotherapy and/or radiotherapy (van den Bent et al., 2005; Cairncross et al., 2006; Wick et al., 2009) .
The molecular mechanisms and the relevant gene(s) underlying the prognostic significance of 1p/19q deletion are still unknown. Recently, mutations in the FUBP1 gene on 1p31.1 and the CIC gene on 19q13.2 have been detected in 1p/19q-deleted oligodendrogliomas in a large-scale sequencing effort (Bettegowda et al., 2011) . A variety of other candidate genes located on 1p have been identified including TP73 (1p36.3), CAMTA1 (1p36), CHD5 (1p36.31), DFFB (1p36), SHREW1 (1p36.32), CITED4 (1p34.2), RAD54 (1p32), CDKN2C (1p32), DIRAS3 (1p31) and NOTCH2 (for recent review see Riemenschneider and Reifenberger, 2009 ). However, none of these genes has been experimentally linked to treatment response in gliomas to date. Using microarray-based expression profiling of gliomas with and without 1p/19q losses, we identified PRDX1 (peroxiredoxin 1) as a candidate gene at 1p34.1 showing significantly reduced expression in the 1p/19q-deleted tumours (Tews et al., 2006) . Proteomic profiling also revealed lower expression of PRDX1 protein in 1p/19q-deleted versus non-deleted oligoastrocytomas (Grzendowski et al., 2010) . In the central nervous system, PRDX1 is primarily expressed in glial cells (Hattori and Oikawa, 2007) . It functions as a thiol reductase involved in oxidative stress defense mechanisms through its ability to catalyse peroxide reduction of reactive oxygen species (ROS), such as H 2 O 2 , organic hydroperoxides and peroxynitrite (for review see Immenschuh and Baumgart-Vogt, 2005) . Prdx1 knockout mice have higher levels of cellular ROS and die prematurely of cancer, indicating a tumour-preventive role of peroxiredoxin 1 (Neumann et al., 2003) . More recently, peroxiredoxin 1 has been reported to inhibit tumourigenesis by binding the tumour suppressor PTEN and protecting PTEN from oxidation-induced inactivation (Cao et al., 2009) .
Increased ROS levels have a major role in mediating the toxicity of radio-and chemotherapy by inducing DNA mutation and DNA damage leading to cell cycle arrest and apoptosis (Wang et al., 2005; Mates et al., 2008) . Upregulation of antioxidant capacity as a consequence of intrinsic oxidative stress in cancer cells, however, can confer radio-and chemotherapy resistance, suggesting targeted redox modulation as a promising novel approach in cancer therapy (Trachootham et al., 2009) . In line with these findings, increased peroxiredoxin 1 expression was found to protect thyroid cells from ROS-induced apoptosis (Immenschuh and Baumgart-Vogt, 2005) . Similarly, overexpression of PRDX1 in lung cancer cells enhanced their clonogenic survival and suppressed apoptosis after ionizing irradiation .
Here, we report that loss of PRDX1 expression in 1p/19q-deleted oligodendrogliomas is frequently due to promoter hypermethylation of the remaining PRDX1 gene copy and demonstrate a significant increase of chemotherapy-and radiation-induced apoptosis upon PRDX1 knockdown in Hs683 glioma cells in vitro.
Results

Frequent 5
0 -CpG island hypermethylation and reduced expression of PRDX1 in 1p/19q-deleted oligodendroglial tumours We analysed 35 CpG dinucleotides of the PRDX1 CpG island in 56 oligodendroglioma patients (14 WHO grade II and 42 WHO grade III tumours) and found an increased methylation in 1p/19q-deleted tumour samples (Figure 1 ). The correlation of 1p/19q loss with PRDX1 CpG-island hypermethylation was highly significant (P ¼ 0.001, Welch's two-sample test, see Figure 2 ). In contrast, no PRDX1 CpG-island hypermethylation was detected in two samples of non-neoplastic brain tissue (NNB1, 2) and leukocyte DNA from five patients with PRDX1-hypermethylated gliomas.
We correlated PRDX1 CpG-island methylation status and PRDX1 mRNA expression determined by quantitative real-time PCR in 40 patients diagnosed with WHO grade II or III gliomas. PRDX1 hypermethylation strongly correlated with decreased PRDX1 expression and vice versa (P ¼ 0.000002, Welch's two-sample test; Supplementary Figure S1 ).
PRDX1 hypermethylation was not detected in any of the 21 primary glioblastomas investigated (Supplementary Figure S2 ). However, 8 of 13 secondary glioblastomas displayed at least partial methylation of the PRDX1 CpG island (Supplementary Figure S2) . Similar to the findings in oligodendroglial tumours, statistical analysis of 23 glioblastoma tumours with available methylation and expression data revealed significantly lower PRDX1 mRNA levels in four hypermethylated glioblastomas as compared with 19 unmethylated tumours (P ¼ 0.03, Welch's t-test; Supplementary Figure S3 ).
PRDX1 protein expression is decreased in oligodendroglial gliomas with 1p/19q loss PRDX1 protein expression was investigated by western blot analysis in 19 oligodendroglial gliomas, including 9 tumours with 1p/19q deletion and 10 tumours without these losses (Figure 3 ). In line with the mRNA data, PRDX1 protein expression was substantially reduced in 1p/19q-deleted tumours when compared with nondeleted tumours (Figure 3 ).
PRDX1 5
0 -CpG-island hypermethylation correlates with IDH1 and IDH2 mutation Mutation analysis of 29 WHO grade II and 27 WHO grade III gliomas for mutations in codon 132 of IDH1 or codon 172 of IDH2 revealed 12 tumours (21%) with wild-type IDH1 and IDH2 genes and 44 tumours (79%) with somatically mutated IDH1 (R132G, R132H, R132S) or IDH2 alleles (R172K, R172M, R172W). The IDH2 R172W mutation identified in one tumour represents a novel mutation that has not been reported before. Correlation between PRDX1 methylation and IDH1/2 mutation showed that the 29 tumours without PRDX1 hypermethylation included 10 IDH1/2-wildtype and 19 IDH1/2-mutant cases. In contrast, among 27 PRDX1-hypermethylated tumours only two lacked IDH1/2 mutations whereas 25 tumours were IDH1/2 mutant. Thus, PRDX1 promoter methylation was not only significantly associated with 1p/19q deletion but also with mutation of IDH1 and IDH2 (P ¼ 0.02, Fisher's exact test).
Silencing of PRDX1 in Hs683 glioma cells leads to an increase in apoptosis The Hs683 cell line is a well-characterized glima cell line originally isolated from an oligodendroglioma (Camby et al., 2000; Belot et al., 2001; Branle et al., 2002; Hubstenberger et al., 2008) . However, in contrast to what has been described before (Branle et al., 2002) , we could not detect deletion of 1p in this cell line (Supplementary Figure S4) . Hence, Hs683 cells express PRDX1 at high transcript and protein levels. Therefore, we chose this oligodendroglioma-like cell line to study the effects of PRDX1 silencing on radio-and chemotherapy. Transduction of Hs683 cells with lentiviral particles containing a PRDX1-targeting short-hairpin (sh)RNA efficiently knocked down PRDX1 mRNA (81%; Figure 4a ) and protein expression (Figure 4b ). CpG sites between nucleotides 4 57 59 879 and 4 57 60 377; ENSG00000117450) from sodium bisulfite-modified DNA followed by direct sequencing. The methylation status at each CpG site was rated according to the following scale: 0, not methylated; 1, weakly methylated (intensity of methylated signal lower than B1/3 relative to unmethylated signal); 2, moderately methylated (intensity of methylated signal approximately equal to unmethylated signal); 3, strongly methylated (intensity of unmethylated signal less than B1/3 of methylated signal). This rating is represented in a grey-scale pattern as indicated below the figure. The presence of allelic losses on 1p and 19q is indicated for each tumour (LOH, loss of heterozygosity). Individual tumours demonstrated evidence of partial deletions on 1p with loss of heterozygosity (LOH) being restricted to distal markers on 1p36 (LOH 1p36) or an interstitial region at 1p34 (LOH 1p34).
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The apoptotic cell fraction was increased upon PRDX1 depletion in comparison with dimethyl sulfoxide (DMSO)-treated controls (3% NT shRNA versus 10% PRDX1 shRNA, Po0.01, Student's t-test; Figure 5b ) as well as with untreated cells (6% versus 26% apoptotic cells; Figure 6b ). However, this latter difference did not reach significance.
In addition, MTS assays revealed a decrease of viable cells after PRDX1 knockdown as compared with the non-targeting shRNA control. After DMSO treatment PRDX1 knockdown cells showed a viability of 89% when normalized to DMSO-treated non-targeting shRNA cells (Po0.01, Student's t-test). Without treatment PRDX1 knockdown cells exhibit a viability of 94% after normalization to untreated non-targeting shRNA cells (Po0.01, Student's t-test).
Silencing of PRDX1 sensitizes Hs683 glioma cells to temozolomide treatment To investigate the possible influence of PRDX1 expression on sensitivity to alkylating chemotherapy, Hs683 cells were incubated with 400 or 600 mM temozolomide (TMZ), respectively. In the non-targeting shRNA-transduced cells, treatment with TMZ increased the apoptotic rate from 3 (DMSO control) to 21% (400 mM TMZ) and 38% (600 mM TMZ) 5 days after drug application. In the PRDX1-silenced cells, TMZ increased the percentage of apoptotic cells from 10 (DMSO control) to 58% (400 mM TMZ) and 74% (600 mM TMZ). Hence, the combination of PRDX1 silencing and TMZ treatment leads to increased apoptosis induction compared with each effect on its own (Figures 5a and b) . The increase in apoptotic rate was significant for PRDX1 knockdown at both TMZ concentrations (Po0.001 for 400 mM TMZ; Po0.05 for 600 mM TMZ, Student's t-test). MTS viability assays were performed under the same conditions and normalized to the value of DMSO-treated cells. In nontargeting shRNA-transduced Hs683 cells, TMZ treatment reduced cell viability to 78% (400 mM TMZ) or 79% (600 mM TMZ). In comparison, PRDX1 shRNA-transduced Hs683 cells demonstrated a significantly stronger reduction in cell viability to 42% after 400 mM TMZ and 33% after 600 mM TMZ, respectively (Figure 5c ). The differences in viability between PRDX1-silenced and control cells were significant for both concentrations (Po0.001 for 400 mM TMZ; Po0.01 for 600 mM TMZ, Student's t-test). Silencing of PRDX1 sensitizes Hs683 glioma cells to ionizing irradiation PRDX1-knockdown cells (Hs683) and non-target shRNA controls were exposed to single doses of 5 or 8 Gy. Apoptosis assays performed 5 days after treatment revealed an increase in the fraction of apoptotic cells from 6 (untreated control) to 16% (5 Gy) and 53% (8 Gy) for the cells transduced with non-targeting shRNA. When PRDX1-knockdown cells were irradiated, the fraction of apoptotic cells increased from 26 (untreated control) to 52% for 5 Gy and to 75% for 8 Gy. Thus, induction of apoptosis was stronger when a combination of PRDX1 silencing and irradiation was used in comparison to application alone (Figures 6a and b) . At a dose of 8 Gy the fraction of apoptotic cells in the PRDX1-silenced cells was significantly higher than in the non-target shRNA-transduced control cells (Po0.05, Student's t-test; Figure 6b ). In non-targeting controls, MTS assays revealed that cell viability was reduced to 82 (5 Gy) and 50% (8 Gy) relative to the PRDX1 hypermethylation in glioma LM Dittmann et al untreated control. Upon PRDX1 silencing, the reduction in cell viability was more pronounced (43% 5 Gy; 23% 8 Gy; Figure 6c) . The difference in cell viability between PRDX1-silenced and non-target shRNA-transduced control Hs683 cells was significant for both doses (Po0.001, Student's t-test).
Discussion
Combined deletion of chromosomal arms 1p and 19q is a powerful prognostic marker in patients with anaplastic oligodendroglial tumours treated with radiotherapy, alkylating chemotherapy or combined radiochemotherapy (Cairncross et al., 2006; van den Bent, 2006; Wick et al., 2009) . To identify genes located on these chromosomal arms that may account for this prognostic effect, we performed microarray-based gene expression profiling comparing oligodendroglial tumours with and without 1p/19q losses (Tews et al., 2006) . Thereby, we identified a set of candidate genes showing significantly reduced mRNA expression levels in 1p/19q-deleted as compared with 1p/19q-intact tumours (Tews et al., 2006) . These included the CITED4 gene at 1p34.2 (Tews et al., 2007) as well as several other genes, among which the peroxiredoxin 1 (PRDX1) gene appeared as a particular promising candidate because (i) it was independently identified in a proteomic screen of lowgrade oligodendroglial tumours (Grzendowski et al., 2010) , (ii) was reported to have tumour-preventive functions (Neumann et al., 2003) and (iii) was linked to radiotherapy response of cancer cells Zhang et al., 2008) . Here, we report on the mechanism leading to the frequent downregulation of PRDX1 mRNA and proteins in 1p/19q-deleted gliomas and provide first evidence for a role of peroxiredoxin 1 in the response of Hs683 glioma cells to TMZ and ionizing irradiation. PRDX1 hypermethylation in glioma LM Dittmann et al the remaining allele of genes located in the deleted chromosomal regions, thereby causing biallelic inactivation of these genes and loss of their expression (Baylin et al., 2001 ). In the current study, sodium bisulfite sequencing analysis of the PRDX1-associated 5 0 -CpG island revealed hypermethylation in the vast majority of 1p/19q-deleted primary gliomas. In fact, oligodendroglial tumours with 1p and 19q deletions showed significantly more frequent PRDX1 5 0 -CpG-island hypermethylation and reduced levels of PRDX1 mRNA when compared with oligodendroglial tumours without these deletions (Supplementary Figure S1) . Furthermore, four gliomas without 1p/19q deletion with hypermethylation showed reduced PRDX1 expression (Figure 2) . Intriguingly, we also found PRDX1 5 0 -CpGisland hypermethylation in a subset of secondary glioblastomas but not in primary glioblastomas. As secondary glioblastomas and oligodendroglial tumours share frequent mutation in the IDH1 and IDH2 genes, we also correlated the PRDX1 methylation status with the IDH1 and IDH2 mutation status in our primary gliomas. This revealed a siginificant association of PRDX1 5 0 -CpG-island hypermethylation not only with 1p/19q deletion but also with IDH1/2 mutation. Interestingly, a CpG-island methylator phenotype has been recently identified in a subset of gliomas that was strongly associated with IDH1 mutation and better outcome (Noushmehr et al., 2010) . Notably, PRDX1 was reported in this study as one of the hypermethylated CpG-island methylator phenotype signature genes.
PRDX1 silencing increases chemo-and radiosensitivity of Hs683 glioma cells in vitro PRDX1 may have different roles in cancer. The finding that loss of Prdx1 in mice leads to premature death from cancer clearly indicates a tumour-preventive function (Neumann et al., 2003) . However, PRDX1 may also support survival of cancer cells and tumour growth by scavenging H 2 O 2 and thereby protecting tumour cells from ROS-induced cell death. Studies in different tumour types showed that ablation of PRDX1 renders cancer cells sensitive to ROS-induced apoptosis (Wang et al., 2005; Bae et al., 2007) . This may also explain our finding that baseline apoptotic activity in Hs683 glioma cells was slightly elevated after PRDX1 knockdown as compared with control-transduced cells. On the other hand, PRDX1 has been reported to inhibit tumourigenesis by binding the tumour suppressor PTEN and protecting PTEN from oxidation-induced inactivation (Cao et al., 2009) . Interestingly, PTEN gene mutations are rare in 1p/19q-deleted and IDH1/2-mutant gliomas but common in primary glioblastomas (Ohgaki and Kleihues, 2009 ), which in turn usually lack 1p/19q deletion, IDH1 mutation and PRDX1 hypermethylation. Thus, inactivation of PRDX1 in 1p/19q-deleted and IDH1/2-mutant gliomas may promote tumour growth by reducing the tumour suppressive function of PTEN. However, this hypothesis requires further experimental validation.
Importantly, we did not only detect frequent 5 0 -CpGisland hypermethylation and reduced expression of PRDX1 in oligodendroglial tumours with 1p and 19q deletions but also provided first evidence that this aberration may be linked to radio-and chemosensitivity of Hs683 glioma cells in vitro. Clinically, it has been well documented in numerous retrospective and prospective studies that 1p/19q deletion in low-grade and anaplastic oligodendroglial tumours predicts response to radiotherapy as well as chemotherapy with TMZ or nitrosourea compounds (Brada et al., 2003; Cairncross et al., 2006; Kouwenhoven et al., 2006; van den Bent, 2006; Wick et al., 2009) . The molecular basis for the predictive power of 1p/19q deletion is still unknown. Mo¨llemann et al. (2005) reported that 1p/19q-deleted oligodendroglial tumours frequently demonstrate promoter hypermethylation and reduced expression of the O(6)-methylguanine DNA methyltransferase (MGMT) gene, an aberration that has been linked to response to TMZ therapy in glioblastoma patients (Hegi et al., 2005) as well as response to chemo-and radiotherapy in anaplastic glioma patients (Wick et al., 2009) . However, although MGMT inactivation undoubtedly is of relevance for TMZ sensitivity (for review see Weller et al., 2010) , a mechanistic role of MGMT in mediating radiosensitivity has not been demonstrated, thus suggesting the involvement of genetic/epigenetic alterations in other genes. Our in vitro results clearly demonstrate that not only TMZ-induced apoptosis is strongly (more than fivefold) increased after PRDX1 silencing in Hs683 cells, but they also show significantly higher sensitivity of PRDX1-knockdown Hs683 cells to ionizing irradiation. The latter finding is in line with data from another group indicating enhanced radiosensitivity of human intestinal cancer cells after adenoviral knockdown of PRDX1 (Zhang et al., 2008) . Similarly, Kim et al. (2006) reported that overexpression of PRDX1 enhances the clonogenic survival of irradiated human lung cancer cells by suppressing radiation-induced c-Jun NH2-terminal kinase activation and apoptosis. Interestingly, this increase in chemo-and radiosensitivity after PRDX1 silencing could not be observed in vitro for glioma cells of non-oligodendroglial origin, that is, the glioblastoma cell line U373MG (Supplementary Figure  S5) , suggesting that U373MG cells exhibit additional pro-survival pathways.
Concerning a possible prognostic role of PRDX1 5 0 -CpG-island hypermethylation and expression in glioma patients, the number of patients with available clinical follow-up data in our tumour series was too low to allow for any reasonable survival correlation. However, univariate analysis of PRDX1 mRNA expression data for The Cancer Genome Atlas cohort of glioblastomas (http://hgserver1.amc.nl/cgi-bin/r2/main. cgi) revealed significantly shorter overall survival for glioblastoma patients whose tumours demonstrated high PRDX1 mRNA expression levels (Supplementary Figure S6) .
In summary, our study demonstrates frequent 5 0 -CpG-island hypermethylation and reduced expression of the PRDX1 gene in oligodendroglial tumours, in particular in 1p/19q-deleted and IDH1/2-mutant tumours. Among the glioblastomas, PRDX1 hypermethylation was found in a subset of secondary glioblastomas but not in primary glioblastomas. Furthermore, we provide first evidence that PRDX1 knockdown increases the sensitivity of cultured oligodendroglioma cells to radiotherapy and chemotherapy with TMZ, thus suggesting that loss of PRDX1 expression due to epigenetic gene silencing contributes to the favourable response of 1p/ 19q-deleted gliomas to cytotoxic therapy.
Materials and methods
Patients' samples
In total, we investigated tumour samples from 93 patients (41 female and 52 male; mean age at operation: 52 years; range: 24-76 years) with different types of gliomas, including 13 oligodendrogliomas WHO grade II (OII), 23 anaplastic oligodendrogliomas WHO grade III (AOIII), 11 oligoastrocytomas WHO grade II (OAII), 12 anaplastic oligoastrocytomas WHO grade III (AOAIII), 21 primary glioblastomas WHO grade IV (pGBIV) and 13 secondary glioblastomas WHO grade IV (sGBIV). The tumour tissue samples were retrieved from the archive of the Department of Neuropathology, Heinich Heine University Du¨sseldorf, and investigated in an anonymized manner as approved by the local institutional review board. As reference tissues, we used non-neoplastic brain tissue samples from cortex and cerebral white matter obtained from two patients who were operated on nonneoplastic lesions. All tissue samples were snap-frozen immediately after resection and stored at À80 1C. The tumours were histologically classified according to the WHO classification of tumours of the central nervous system (Louis et al., 2007) . Only specimens with a tumour cell content of at least 80% were used for nucleic acid extraction. Peripheral blood samples for extraction of constitutive (leukocyte) DNA were available from five patients.
Nucleic acid extraction and microsatellite analysis for loss of heterozygosity on 1p and 19q Extractions of high molecular weight DNA and RNA from frozen tumour samples as well as DNA from peripheral blood samples were carried out as reported before (van den Boom et al., 2003) . At least five microsatellite loci located on 1p (D1S200, D1S211, D1S507, D1S489, D1S468) and five microsatellite loci located on 19q (D19S572, D19S219, D19S1182, D19S596, D19S210) were assessed for allelic losses in each tumour as reported elsewhere (Felsberg et al., 2004) . Three of the five microsatellite loci from 1p map distally and two proximally to the PRDX1 locus.
Analysis of PRDX1 for promoter methylation and mRNA expression The methylation status of the PRDX1-associated CpG island, as defined in the UCSC Genome Browser (http://genome.ucsc. edu) was assessed by sequencing of sodium bisulfite-modified DNA (for details see Supplementary information). For PRDX1 gene expression analysis, quantitative real-time PCR was performed as described elsewhere (Korshunov et al., 2003) using the following PRDX1-specific primers: FOR 5 0 -CAGC CTGTCTGACTACAAAGGA-3 0 and REV 5 0 -CCAGTCCTC CTTGTTTCTTAGG-3 0 . Expression levels of PRDX1 mRNA were normalized to those of three housekeeping genes, namely phosphoglycerate kinase 1 (PGK1), lamin B1 (LMNB1) and cyclophilin A (PPIA).
IDH1 and IDH2 mutation analysis Mutational analysis of the IDH1 and IDH2 genes was performed by direct sequencing of PCR products spanning the sequence of codon 132 of the IDH1 gene or codon 172 of the IDH2 gene as described elsewhere (Felsberg et al., 2010) .
Protein extraction and western blot analysis Protein fractions from tumour samples were obtained as described elsewhere (Grzendowski et al., 2009) . Western blots were probed with antibodies against human PRDX1 protein (1:1000; Abcam, Cambridge, UK) and b-tubulin (1:2000; Sigma-Aldrich, Munich, Germany) or b-actin (1:5000; Santa Cruz Biotechnology, Santa Cruz, CA, USA) to assess protein loading. Glioma cells were lysed and protein extracts were purified using the All Prep RNA/Protein Kit (Qiagen, Hilden, Germany).
Silencing of PRDX1 by lentiviral transduction of shRNA constructs Lentiviral particles were produced by co-transfecting pMD2.G, psPAX2 and pLKO.1 constructs (MISSION TRCHs 1.0; Sigma-Aldrich Corporation, St Louis, MO) in HEK293T cells (Moffat et al., 2006) using FuGENE6 (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's instruction. Viruses were harvested by ultracentrifugation 48 h after transfection. Infection of Hs683 glioma cells (ATCC, Manassas, VA, USA) was carried out in the presence of 8 mg/ml polybrene (Chemicon, Billerica, MA, USA). Viruscontaining supernatant was removed after 24 h. Two independent shRNA constructs targeting different regions of the PRDX1 mRNA transcript were used (MISSION shRNA NM_002574.2-800s1c1 and NM_002574.2-512s1c1). Non-targeting shRNA (MISSION SHC002) was used as a control. Quantification of PRDX1 mRNA knockdown was performed by real-time PCR as described above.
Irradiation and TMZ treatment
For assessment of TMZ concentrations and doses of radiation the protocol of Hermisson et al. (2006) was adapted. Cytotoxicity assays were done afterwards to optimize the doses for Hs683 cells (data not shown). Hs683 glioma cells stably expressing PRDX1-specific or control shRNA constructs were irradiated with 5 or 8 Gy using a 137 Cs source (Gammacell 1000, AECL, Edmonton, AB, Canada) in six-well plates (NUNC, Rochester, NY, USA) with 150 000 cells/well. For TMZ treatment, these cells were incubated with 400 or 600 mM TMZ (Tocris Bioscience, Ellisville, MO, USA) for 6 h. For this purpose, TMZ was dissolved at 100 mM in DMSO (Sigma-Aldrich) and was diluted afterwards in Dulbecco's modified Eagle's medium to the desired concentrations. The same amount of DMSO was used as a vehicle control.
Assessment of cell viability
The MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) CellTiter96 AQ Non-Radioactive Cell Proliferation Assay (Promega, Mannheim, Germany) was used following the manufacturer's recommendations. Experiments were performed three times independently with each sample being assayed in triplicate.
Detection of apoptosis by annexin V and propidium iodide staining For detection of apoptotic activity, treated and control Hs683 cells were incubated with annexin V-FITC (BD-Bioscience, San Diego, CA, USA) and propidium iodide (Invitrogen,
